Chiasma, a privately held biopharma company, announced that it closed a $38.5 million equity financing co-led by new investor Abingworth and current investor MPM Capital. The round also included investments from existing shareholders. The proceeds will be used complete the phase 3 trial of Octreolin, the company’s proprietary oral form of the peptide octreotide, which is planned to be completed in the second quarter of 2013. Chiasma, based in Jerusalem, is developing oral drugs that previously were only available by injection, thereby providing patients with pain-free medications that are self-administered.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments